Yusimry, a Humira Biosimilar Product, Gets FDA Approval
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Ulcerative Colitis
Maintenance of Clinical Remission Observed With Mirikizumab in UC Trial
LUCENT-2 is a maintenance study evaluating the efficacy and safety of mirikizumab in patients who achieved clinical response in the 12-week LUCENT-1 induction study.
Study Investigates Rate of Antidrug Antibody Formation to Biologics Used in IBD
Given that immunogenicity to biologics may contribute to IBD treatment failure, the study authors sought to determine the rate of ADA formation to individual biologic agents.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Ozanimod Beats Placebo for Ulcerative Colitis
Once-daily oral ozanimod more effective than placebo for moderately to severely active ulcerative colitis
Statins ID’d as Potential Therapy for Ulcerative Colitis
People with ulcerative colitis taking statins, regardless of their age, have nearly half the colectomy rates
AbbVie Seeks Approval of Upadacitinib for Ulcerative Colitis
The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.
Corticosteroid Use Declines in Patients With IBD Over Past 20 Years
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial
A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
Zeposia Approved for Moderately to Severely Active Ulcerative Colitis
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
